Search Results - kenneth+witwer

4 Results

Sort By:

Short Viral RNAs (svRNAs) with Theragnostic Potential in Infection with SARS-CoV-2 and Related Viruses

Value PropositionNovel Biomarkers for Diagnosis & PrognosisInsights into viral immune evasion mechanism Identify key host pathways targeted by svRNAs Novel Therapeutic TargetsIdentified pathways enable the development of immune-modulating therapies. Unmet NeedStudies have show than SARS-CoV-2 employs various mechanisms to evade the host’s innate...

Published: 6/27/2025 | Inventor(s): Kenneth Witwer, Tom Driedonks, Andrey Turchinovich

Keywords(s):

Category(s):

ExoBLAze Assay: Efficient Quantification of EV Content Delivery

Value Proposition· Specific, FRET-based detection: only quantifies successful EV endosomal escape· Reliable and adaptable: assay works with variety of Evs, target cell types, and fluorescence detection methods· Genetic modification-free: does not require any genetic engineering of target cells· Ground-breaking solution: first proposed...

Published: 6/27/2025 | Inventor(s): Sarah Marquez, Zach Troyer, Kenneth Witwer

Keywords(s):

Category(s): Technology Classifications > Diagnostics

Engineered Extracellular Vehicles as a selective drug delivery platform

Value Proposition:· Engineered extracellular vesicles with enhanced uptake and reduced immunogenicity · Improved EV-based drug delivery platform Technology DescriptionResearchers at Johns Hopkins have identified endogenous proteins that can be engineered to assist in extracellular vesicle and/or nanoparticle therapeutics through increased...

Published: 6/27/2025 | Inventor(s): Kenneth Witwer, Zach Troyer

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Genetic Diseases, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics

Culture-derived EVs for targeted delivery and treatment of B cell diseases

Value Proposition· Purified EVs with preferential targeting for B cells in both ex-vivo and in-vivo applications.· EVs have half-life between 30-40 minutes, longer than many comparable extracellular vesicles.· EVs purified from cell culture medium to increase throughput, speed, and development of B-cell targeted therapies. Technology...

Published: 6/27/2025 | Inventor(s): Kenneth Witwer, Tom Driedonks, Erin Shirk, Linglei Jiang, Olesia Gololobova

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms